Samit Hirawat

ASH: Abecma's overall survival data show why FDA called adcomm

BMS' Abecma showed no overall survival advantage over existing combination regimens in another case of control arm crossovers hurting the key readout.

Angus Liu Dec 11, 2023 7:30pm

BMS aims for staggering 25 label expansions in the coming years

Sep 15, 2023 12:04pm

Abecma's 3rd-line myeloma data not selected by ASH22

Dec 12, 2022 5:08pm

BMS opens 3rd checkpoint inhibitor class

Mar 18, 2022 7:23pm